Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Bosentan

Drug and asset intelligence for Bosentan with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Zydus Pharmaceuticals →

Mechanism of action

Endothelin Receptor Antagonist

Recent signals(4)

RegulatoryJuly 26, 2026

FDA Submission Update for Bosentan by Zydus Pharms

Zydus Pharms has submitted a supplemental application for Bosentan under ANDA207760, currently under standard review.

RegulatoryJuly 26, 2026

FDA Grants AP Status for Bosentan ANDA207110 by Watson Labs

The FDA has granted approval status (AP) for Watson Labs' ANDA207110 for Bosentan.

July 3, 2026

FDA Approval Status Update for Bosentan ANDA207760 by Zydus Pharmaceuticals

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Bosentan submitted by Zydus Pharmaceuticals.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for Bosentan by Natco Pharma

The FDA has accepted a supplemental application for Bosentan submitted by Natco Pharma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Zydus Pharmaceuticals — Bosentan

July 3, 2026 · N/A

Topline Data

— Bosentan

June 27, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology · Endothelin Receptor Antagonist →

Cardiology · Pulmonary Hypertension →

Endothelin Receptor Antagonist →

Pulmonary Hypertension →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.